Abstract
Lung cancer surfaces to be the predominant determinant of mortality worldwide constituting 13% and 19% of all new cancer cases and deaths related to cancer respectively. Molecular profiling has now become a regular trend in lung cancer to identify the driver mutations. Epidermal Growth Factor Receptor (EGFR) is the most regular driver mutation encountered in Non-Small Cell Lung Cancer (NSCLC). Targeted therapies are now available for the treatment of EGFR mutant NSCLC. EGFR mutation is more frequently expressed in adenocarcinoma than squamous cell carcinoma. This article presents a detailed molecular insight of the therapeutic approaches for the treatment of EGFR mutant lung cancer. The article delineates molecular mechanism of the drugs that are approved, the drugs that are in clinical trial and the drugs that have not entered a clinical trial but shows promising future in the treatment of EGFR mutant lung cancer. Furthermore, this article provides concise information on relevant combinational or monotherapy clinical trials that have been completed for various approaches.
Keywords: Lung cancer, epidermal growth factor receptor, epidermal growth factor receptor protein-tyrosine kinase, monoclonal antibodies, ubiquitin, heat-shock protein, histone deacetylase.
Current Cancer Drug Targets
Title:Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer
Volume: 18 Issue: 8
Author(s): Dhaval Sanchala, Lokesh K. Bhatt*Kedar S. Prabhavalkar
Affiliation:
- Department of Pharmacology, SVKM`s Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai,India
Keywords: Lung cancer, epidermal growth factor receptor, epidermal growth factor receptor protein-tyrosine kinase, monoclonal antibodies, ubiquitin, heat-shock protein, histone deacetylase.
Abstract: Lung cancer surfaces to be the predominant determinant of mortality worldwide constituting 13% and 19% of all new cancer cases and deaths related to cancer respectively. Molecular profiling has now become a regular trend in lung cancer to identify the driver mutations. Epidermal Growth Factor Receptor (EGFR) is the most regular driver mutation encountered in Non-Small Cell Lung Cancer (NSCLC). Targeted therapies are now available for the treatment of EGFR mutant NSCLC. EGFR mutation is more frequently expressed in adenocarcinoma than squamous cell carcinoma. This article presents a detailed molecular insight of the therapeutic approaches for the treatment of EGFR mutant lung cancer. The article delineates molecular mechanism of the drugs that are approved, the drugs that are in clinical trial and the drugs that have not entered a clinical trial but shows promising future in the treatment of EGFR mutant lung cancer. Furthermore, this article provides concise information on relevant combinational or monotherapy clinical trials that have been completed for various approaches.
Export Options
About this article
Cite this article as:
Sanchala Dhaval , Bhatt K. Lokesh *, Prabhavalkar S. Kedar , Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer, Current Cancer Drug Targets 2018; 18 (8) . https://dx.doi.org/10.2174/1568009617666170623123848
DOI https://dx.doi.org/10.2174/1568009617666170623123848 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Notch Signaling Proteins: Legitimate Targets for Cancer Therapy
Current Protein & Peptide Science AKT Signaling in Regulating Angiogenesis
Current Cancer Drug Targets Targeting the Epidermal Growth Factor Receptor Family in Radionuclide Therapy of Tumors – Signal Transduction and DNA Repair
Letters in Drug Design & Discovery Pharmacogenomics of Non-Small Cell Lung Cancer
Current Pharmacogenomics Understanding Mouse Skin Carcinogenesis through Transgenic Approaches
Current Genomics Genome-wide Differential-based Analysis of the Relationship between DNA Methylation and Gene Expression in Cancer
Current Bioinformatics Folate Based Radiopharmaceuticals for Imaging and Therapy of Cancer and Inflammation
Current Pharmaceutical Design Advances of AKT Pathway in Human Oncogenesis and as a Target for Anti-Cancer Drug Discovery
Current Cancer Drug Targets Therapeutic Targeting of Cancers with Loss of PTEN Function
Current Drug Targets Dendrimers in Therapy for Breast and Colorectal Cancer
Current Medicinal Chemistry Plant Polyphenols and Oral Health: Old Phytochemicals for New Fields
Current Medicinal Chemistry The SCF-type E3 Ubiquitin Ligases as Cancer Targets
Current Cancer Drug Targets Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine The miRNAs and Epithelial-Mesenchymal Transition in Cancers
Current Pharmaceutical Design The Vitamin D/CYP24A1 Story in Cancer
Anti-Cancer Agents in Medicinal Chemistry Unequivocal Role of Pyrazine Ring in Medicinally Important Compounds: A Review
Mini-Reviews in Medicinal Chemistry Comparison Between the Maximum Standard Uptake Value and the Ratio of Lymph Node to Primary Tumor Attenuation in Head and Neck Cancers: A Prospective Study
Current Medical Imaging A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma
Current Cancer Drug Targets The Re-Emergence of Aerosol Gene Delivery: A Viable Approach to Lung Cancer Therapy
Current Cancer Drug Targets Cytotoxicity Evaluation of Dimethoxy and Trimethoxy Indanonic Spiroisoxazolines Against Cancerous Liver Cells
Current Chemical Biology